Top Markets
Coin of the day
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
Classificação em ações #32327
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Preço da ação
$0.88
Última sincronização: 2026-08-17
Valor de mercado
$10.41M
Variação (1 dia)
-7.26%
Variação (1 ano)
-50.56%
País
SG
Negociar CytoMed Therapeutics Limited (GDTC)

Categoria

EPS de CytoMed Therapeutics Limited (GDTC)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da CytoMed Therapeutics Limited, o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da CytoMed Therapeutics Limited de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE